Impact at cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction

被引：26

作者：

Ochiai, M ^{[1
]}

Eto, K ^{[1
]}

Takeshita, S ^{[1
]}

Yokoyama, N ^{[1
]}

Oshima, A ^{[1
]}

Kondo, K ^{[1
]}

Sato, T ^{[1
]}

Isshiki, T ^{[1
]}

机构：

[1] Teikyo Univ, Sch Med, Dept Med Cardiol, Itabashi Ku, Tokyo 1738605, Japan

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 1999年 / 84卷 / 09期

关键词：

D O I：

10.1016/S0002-9149(99)00501-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significantly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.

引用

页码：1074 / +

页数：5

共 20 条

[1] A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction - Results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial [J].

Antoniucci, D ;

Santoro, GM ;

Bolognese, L ;

Valenti, R ;

Trapani, M ;

Fazzini, PF .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (06) :1234-1239

[2] MECHANISMS OF RESTENOSIS AND REDILATION WITHIN CORONARY STENTS - QUANTITATIVE ANGIOGRAPHIC ASSESSMENT [J].

GORDON, PC ;

GIBSON, CM ;

COHEN, DJ ;

CARROZZA, JP ;

KUNTZ, RE ;

BAIM, DS .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 21 (05) :1166-1174

[3]

IKEDA Y, 1987, ARZNEIMITTEL-FORSCH, V37-1, P563

[4]

Kastrati A, 1997, CIRCULATION, V96, P462

[5] The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells [J].

Kayanoki, Y ;

Che, WY ;

Kawata, S ;

Matsuzawa, Y ;

Higashiyama, S ;

Taniguchi, N .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (02) :478-481

[6]

KIMURA Y, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1144

[7] PHARMACOLOGICAL TREATMENT OF INTIMAL HYPERPLASIA AFTER METALLIC STENT PLACEMENT IN THE PERIPHERAL ARTERIES - AN EXPERIMENTAL-STUDY [J].

KUBOTA, Y ;

KICHIKAWA, K ;

UCHIDA, H ;

MAEDA, M ;

NISHIMINE, K ;

MAKUTANI, S ;

SAKAGUCHI, S ;

YOSHIOKA, T ;

OHISHI, H ;

KIMURA, Y ;

YOSHIKAWA, T .

INVESTIGATIVE RADIOLOGY, 1995, 30 (09) :532-537

[8] Comparison of primary coronary stenting to primary balloon angioplasty with stent bailout for the treatment of patients with acute myocardial infarction [J].

Mahdi, NA ;

Lopez, J ;

Leon, M ;

Pathan, A ;

Harrell, L ;

Jang, IK ;

Palacios, IF .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (08) :957-963

[9] Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor [J].

Morishita, R ;

Higaki, J ;

Hayashi, SI ;

Yo, Y ;

Aoki, M ;

Nakamura, S ;

Moriguchi, A ;

Matsushita, H ;

Matsumoto, K ;

Nakamura, T ;

Ogihara, T .

DIABETOLOGIA, 1997, 40 (09) :1053-1061

[10]

NISHI T, 1985, CHEM PHARM BULL, V33, P1140

← 1 2 →